Pioneering Efforts to Combat 'Forever Chemicals'
Cambiotics is stepping into some uncharted territory—tackling the tricky problem of PFAS accumulation in firefighters. If you’ve been following this, PFAS, or per- and polyfluoroalkyl substances, have been living rent-free in our bodies for years. Used in firefighting equipment and foams, these chemicals stick around, affecting anyone exposed. Now, Cambiotics is launching a clinical trial to see if their probiotic strain, 46-SL1, can help the body kick these out.
The Clinical Trial Breakdown
This isn’t just another lab test—this is real-world stuff. Seventy firefighters are strapping in for a double-blind, placebo-controlled crossover trial, measuring changes in serum PFAS concentrations. Safety and tolerability? They’re on the list, too, alongside fecal microbiome changes. Props to Atlantia Clinical Trials in Chicago for running the show. It's a big leap from Cambiotics' lab work, but without initiatives like this, we’re just treading water against these tough compounds.
Why Firefighters?
Alright, why focus on firefighters? These folks inhale and encounter PFAS through their protective gear and foams. It’s in the nature of the job. But here’s the kicker—PFAS are pervasive. The CDC has found traces in over 99% of the U.S. population. While Cambiotics targets the most exposed, the implications could ripple much wider—think potential future applications in reducing PFAS exposure for the general public.
“We are deeply grateful to the clinical team and the firefighters participating.” — Peter Holme Jensen, CEO, Cambiotics
Science Meets Execution
So, Cambiotics isn’t wandering in the dark here. Their approach comes straight out of PhD research flagged in Nature Microbiology in 2025. Anna E. Lindell’s work discovered human gut bacteria that could potentially bioaccumulate PFAS and aid in its elimination. It’s this scientific backbone that pushed Cambiotics to the front lines in PFAS reduction with their first human clinical trial in the U.S.
Funding the Fight Against PFAS
Jumping into clinical trials isn’t cheap, especially in the biotech realm. Cambiotics closed a EUR 4 million Seed investment round earlier this year, thanks to Collaborative Fund, EIFO, and True. It’s a cash injection that's pivotal for Cambiotics' mission—not just for this trial but also for rolling out their first dietary supplement expected by early 2027. Watching how this financial model plays out will be key, given the health impact potential.
Looking Forward
What’s at stake here isn’t just science—it’s the health of communities. While this trial is specific to firefighters, the broader objective is to address a ubiquitous chemical burden on all of us. If Cambiotics’ probiotic shows favorable results, it could open doors to widespread applications. Investors and health advocates alike should keep a keen eye on the data it yields.
For now, Cambiotics is setting the stage with a promise of reducing harmful chemical loads. Whether they can turn heads with impactful results is what folks are waiting to see. Keep your eye on this one—it’s more than just another study. It’s potentially the start of changing how we deal with stubborn, omnipresent health threats.
